Labcorp announced in a press release that their liquid biopsy test, Labcorp Plasma Complete, is now clinically available.
The laboratory-developed test (LDT) “detects genomic alterations in ctDNA across 521 genes.” It allows oncologists to “perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.” The liquid biopsy assay “covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments and clinical trial eligibility.”
Additionally, “Labcorp Plasma Complete also provides clear and comprehensive clinical reports supported by robust bioinformatics, simplifying the interpretation of complex genomic data and reducing the burden on oncologists.”
Validation studies demonstrating the reliability of the test are published in Journal of Molecular Diagnostics.
